Global Rubella Elimination Advances, But Gaps Remain

Key Takeaways

• Worldwide RCV1 coverage among infants aged 12–23 months increased from 39% in 2012 to 73% in 2024.
• Routine RCV introduction reached 179 of 194 countries and verified rubella elimination reached 117 countries by 2024.
• Modeled annual CRS cases declined from 101,381 to 26,859 over the study period.
• Reported rubella cases fell overall but were increasingly concentrated in the African Region by 2024.
• Approximately 21 million infants lived in the 15 countries without routine RCV introduction in 2024.

Rubella infection during early pregnancy is a preventable cause of miscarriage, stillbirth, fetal death, and congenital anomalies, keeping elimination a live issue for infectious disease, pediatric, and obstetric practice. Transmission persists where vaccine introduction, routine coverage, and surveillance remain uneven, allowing endemic circulation to continue and importations to threaten areas that have already interrupted spread. That unresolved global elimination challenge framed a 2012 through 2024 review of rubella and congenital rubella syndrome trends.

Investigators reviewed 2012-2024 electronic Joint Reporting Form data in the Morbidity and Mortality Weekly Report (MMWR) worldwide rubella and congenital rubella syndrome elimination update on rubella-containing vaccine (RCV) introduction, routine coverage, rubella surveillance, congenital rubella syndrome (CRS) surveillance, and elimination verification across 194 countries. First-dose coverage estimates came from World Health Organization and UNICEF national immunization coverage estimates built from administrative data, official country estimates, and coverage surveys. CRS estimates were generated with a dynamic transmission model summarized as the median of 1,000 bootstrap estimates, and elimination required interruption of endemic transmission for at least 36 months with adequate surveillance and regional verification. Analyses emphasized 2012, 2019, and 2024 and compared trends across World Health Organization regions and World Bank income groups.

Routine RCV introduction expanded from 132 of 194 countries (68%) in 2012 to 179 of 194 (92%) in 2024. Global first-dose RCV coverage among infants aged 12–23 months rose from 39% to 73%. In 2024, regional coverage ranged from 37% in the African Region to 96% in the South-East Asia Region, and introduction was universal in the Americas, Europe, South-East Asia, and Western Pacific regions. The remaining gaps were concentrated in lower-resource settings.

Reported rubella cases declined from 94,277 in 2012 to 31,593 in 2024 after a low of 18,881 in 2022, and the African Region accounted for the largest share by 2024. Reported CRS cases increased from 302 in 2012 to 611 in 2024, likely reflecting in part expanded CRS surveillance, while modeled annual CRS cases declined by 73.5%, from 101,381 to 26,859. Verified rubella elimination increased from 84 countries in 2019 to 117 of 194 countries (60%) in 2024, including all 35 countries in the Americas and 50 of 53 in Europe. Those patterns were consistent with broader elimination progress even as CRS case finding became more sensitive.

Surveillance and immunization data quality varied across countries, and COVID-19 disrupted reporting and surveillance performance in ways that complicate year-to-year comparisons. Reported CRS counts likely underestimate true burden because many countries rely on sentinel or referral-based systems that are not nationally representative, and modeled CRS estimates depended on seroprevalence availability and assumptions including independence of second-dose vaccination from first-dose receipt. Even with those limitations, approximately 21 million infants, representing 16% of the global birth cohort, lived in the 15 countries without routine RCV introduction in 2024.

The authors concluded that progress toward rubella and CRS elimination was substantial but incomplete, with gains in vaccine introduction, coverage, and verified elimination occurring alongside a marked modeled decline in CRS burden. They noted that as long as rubella virus continues to circulate anywhere, importation risk remains and the remaining countries without routine RCV introduction continue to define the unfinished part of global elimination.

Clinician Questions

How much did global rubella vaccine coverage increase between 2012 and 2024?

Global first-dose RCV coverage among infants aged 12-23 months increased from 39% in 2012 to 73% in 2024.

How many countries had verified rubella elimination by 2024?

By 2024, 117 of 194 countries, or 60%, had verified rubella elimination, up from 84 countries in 2019.

What happened to congenital rubella syndrome burden worldwide from 2012 to 2024?

Worldwide modeled annual CRS cases declined by 73.5%, from 101,381 in 2012 to 26,859 in 2024, while reported CRS cases increased from 302 to 611 as surveillance expanded.